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Abstract: Until recently, the small bowel was considered a ‘no man’s land’ as the imaging 
modalities available for its investigation were laborious, invasive, costly, or involve significant 
radiation exposure. Wireless capsule endoscopy (WCE) has changed the field dramatically, over 
the last eight years. The established indications for small bowel WCE are obscure gastrointestinal 
bleed/anemia, Crohn’s disease, hereditary polyposis syndromes, and to a lesser extent, evaluation 
of side effects of nonsteroidal anti-inflammatory medications and coeliac disease. We herein 
present an overview of the capsule examination, which seems to be a quickly improving area. 
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Introduction
Since its introduction into clinical practice during the last decade, wireless capsule 
endoscopy (WCE) is now widely accepted as a first-line examination technique for the 
small bowel. Published medical literature now includes several high impact papers, 
as well as a large number of reviews on the various capsule endoscopy modalities 
employed today. A total of more than 700,000 wireless video capsules (WVC) have 
been swallowed since 2001; this number rises exponentially since an introduction of 
this service to several major district hospitals and tertiary centers around the world. 
The aim of this paper is to review available equipment and devices, their indications for 
clinical use (along with potential complications) and potential future applications.
History and progress
Until recently, the small bowel was considered the ‘no man’s land’ of the gastrointestinal 
tract (GI) tract as the imaging modalities available for investigation of this area (ie, small 
bowel follow through, CT enteroclysis, and push enteroscopy) are laborious, invasive, 
costly, and involve significant radiation exposure. These issues do not apply to WCE 
and, whilst more traditional methods of small bowel imaging are still utilized, diagnostic 
yield of these techniques falls short when compared with WCE.1,2
Τhe examination of the small bowel is currently possible using WCE systems 
available from a handful of manufacturers ie, PillCam® SB2 (Given Imaging, Yoqneam, 
Israel), the Olympus EndoCapsule® (Olympus, Tokyo, Japan), and the OMOM® 
capsule (ChongQing JinShan Science & Technology Co., Ltd, ChongQing, China). 
The WVC is an ingestible camera of cylindrical shape, which is not bigger than a 
vitamin pill (11 × 26 mm, weight 3.7 gr) and an image capture rate of two frames per 
second. The camera is powered by a battery with an approximate life of eight hours. Clinical and Experimental Gastroenterology 2009:2 112
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This equates to more than 50,000 images per test (average 
duration 7–8 hours). Newer generation WVCs (from 2008 
onwards) offer an advanced automatic light control system 
and a wider angle of view (156° vs 140°). They provide 1:8 
magnifications, and an estimated 1–30 mm depth of view.
The images are transmitted, via digital radio frequency 
communication, to external electrode sensors. These are 
placed in the lower chest and abdomen in a predetermined 
pattern and the transmitted digital images are stored in a 
lightweight data recorder, which patients can wear on their 
waist or carry like a handbag for the duration of the test. The 
recorder has a rechargeable battery, and the acquired images 
are downloaded onto the reading platform for review. The 
Korean company, Intromedic, has also recently released its 
MiroCam® capsule for use in small bowel investigations. The 
MiroCam® technical specifications include longer battery 
lifetime (11 hours), high-resolution image capture, a sam-
pling rate of three frames per second, and an alternative, 
conductive method of data transmission. However, no data 
are currently available regarding its clinical use.3
Given Imaging (Yoqneam, Israel) also market an esopha-
geal (the PillCam®Eso2) and a colon (the PillCam®Colon) 
capsule. The esophageal capsule has been available for clinical 
use since 2004. It is similar in size to the enteric capsule, but 
is equipped with two optical domes instead of one, allowing 
an image capture rate of 14 images per second (seven images 
per optical dome). It is due to this high capture rate and 
accelerated battery depletion that the operating time of the 
esophageal capsule is limited to 20 min.3 The colonic capsule 
was released in 2006. It is larger than the company’s enteric 
capsule (11 × 31 mm vs 11 × 26 mm). It has two optical domes 
capturing two frames per second each, and a wide angle of 
view similar to that of the updated enteric capsule. Despite 
the fact that both the esophagus and colon are easily acces-
sible to conventional endoscopes, potential complications 
arising from diagnostic endoscopic investigations have a 
reasonable mortality rate4 and WCE may be a useful alter-
native in those patients in whom invasive techniques are 
contraindicated (eg, multiple co-morbidities). WCE may also 
be used in patients intolerant of conventional endoscopy or as 
a supplemental technique in GI-screening programs.
Additional technologies  
and advancements
Reader station software of the GIVEN system has been 
significantly updated and now offers higher quality images, 
faster image download time, and aids to image review. 
A handheld device (connected via USB port with the data 
recorder) is now frequently used which gives the investigator 
the ability to follow the capsule in a real-time mode and 
confirm the capsule entry into small bowel and colon. 
Using this device, failed studies due to gastric retention are 
minimized as prokinetics may be administered to aid transit 
of the capsule through the pylorus. Retention further down 
the GI tract is also immediately apparent avoiding delays 
in taking remedial action. This equipment is not widely 
available yet, but it is hailed as the next step in improvement 
of the diagnostic algorithm for obscure/occult GI bleed and 
stricturing Crohn’s disease.
The potential problems of capsule retention can be 
minimized using radiology and/or the patency (Agile®) capsule. 
The capsule currently in use (second generation – Agile® 
from Given Imaging) has a centrally placed radiofrequency 
identifiable tag (13 × 3 mm,with a tiny antenna and magnet, 
but no battery) which can receive electromagnetic waves 
at a frequency of 128 KHz, it then emits similar waves at 
64 KHz. The device is contained in a lactose shell, which 
dissolves quickly and completely once inside the GI 
tract. It also contains a small amount of barium to enable 
fluoroscopic visualization (if needed). The lactose shell 
itself is contained within an outer plastic coat that prevents 
entrance of digestive fluids into the capsule. The capsule 
is complete with two timer plugs on both sides, which are 
designed to resolve over a period of 12 hours. Excretion of 
the patency capsule can be confirmed by X-ray or through 
the handheld scanner that will detect the emitted electro-
magnetic signal. If the patency capsule is excreted within 
30 hours of ingestion, or if it is excreted intact, the patient 
can then safely undergo WCE.
As with most tests, WCE requires prior patient consent, 
despite being one of the safest procedures in gastroenterology. 
The informing health care provider will have to fully explain 
the procedure to the patient as well as mention the potential 
complications of the procedure. These are retention of the 
capsule, inconclusive findings, contraindication of magnetic 
resonance imaging (MRI) until capsule passage is confirmed, 
and finally capsule aspiration.5–7 Initially the presence of 
indwelling cardiac pacemaker/implantable defibrillator or 
other electromedical devices was considered a contraindica-
tion to WCE; however, recent data suggest that the radiofre-
quency signal of the capsule endoscope does not interfere 
significantly with cardiac pacemakers.3,9 In patients with 
swallowing difficulties, in children, and in cases where the 
device has previously failed to enter the small bowel, even 
after the use of prokinetics, the capsule can be introduced 
into the duodenum with the use of an endoscope and either Clinical and Experimental Gastroenterology 2009:2 113
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a Roth® net or the specially designed AdvanCE® delivery 
device.
All patients should attend the day of their test after a 
12-hour fast and medications such as iron tablets, opiates, 
and antimony drugs should be avoided for a few days prior to 
the test. Some centers advise the use of polyethylene glycol 
(PEG) electrolyte purgative solution in order to improve 
bowel cleanliness, however there is accumulating evidence 
that bowel preparation has questionable benefits in WCE. 
Most units in UK do not use bowel preparation.10–12
The major task after obtaining the video sequence is 
analysis of the data. There are still many areas of concern as 
to accreditation of gastroenterology trainees for interpretation 
of WCE data, ideal reading conditions (ie, distance from the 
screen, amount of light in the room, reading speed, and time 
required for careful and complete reading) and the involve-
ment of nonspecialized medical health care professionals in 
data interpretation.13
Indications
The established indications for small bowel WCE are obscure 
GI bleed, investigation of Crohn’s disease, hereditary polypo-
sis syndromes, and to a lesser extent, evaluation of side effects 
of nonsteroidal anti-inflammatory medications (NSAIDs) 
and coeliac disease.14
Obscure GI bleeding (OGIB)
Obscure bleeding, defined as recurrent episodes of GI bleeding 
(ie, melaena, hematemesis or hematochezia), a positive fecal 
occult blood (FOB) test, or chronic iron deficiency anemia, 
is by far the most frequent indication for WCE. A recent 
meta-analysis confirmed the superiority of WCE against all 
other modalities (including push enteroscopy, but not double 
balloon enteroscopy [DBE] or mesenteric angiography) in 
patients with obscure GI bleeding.2 In a meta-analysis in 
which cumulative data of all the double balloon enteroscopy 
studies against the use of WCE, the diagnostic yield of the 
two procedures was found to be fairly similar.15 A very recent 
multicenter study of the concordance of capsule endoscopy 
and DBE showed good agreement for vascular and inflam-
matory lesions, but not for polyps or neoplasia. DBE seems 
to provide valuable adjunctive information, particularly in 
patients with neoplasia or polyp at capsule endoscopy. DBE 
clarified the origin of bleeding in two-thirds of patients with 
capsule endoscopy showing only blood in the lumen.16
Pennazio and colleagues have shown that WCE has a 
higher diagnostic yield in patients with ongoing intestinal 
bleeding at the time of the procedure, or when the procedure 
was done soon after the bleeding episode.17 On the other 
hand, the positive predictive value of WCE is inversely 
correlated with the overall diagnostic yield; therefore every 
lesion found by WCE should not be regarded as a relevant 
source of bleeding.3
A recent study from Scotland showed that a negative 
WCE study in patients with OGIB is associated with a 
low rate of recurrent bleeding in the long term (11%). 
The investigators suggested an expectant approach with these 
patients, thus avoiding the need for unnecessary additional 
investigations.18
Investigators from Greece demonstrated that in patients 
with obscure GI bleeding, a diagnostic WCE is more 
likely to lead to therapeutic interventions and a favorable 
outcome. Patients, who had a previously noninformative 
test, would definitely benefit from a second-look WCE, 
if the bleeding presentation changes from occult to overt, or 
if the hemoglobin value drops 4 g/dL.19
Crohn’s disease
Historically, the diagnosis of Crohn’s disease has been based 
on clinical, hematological, biochemical, radiological, and 
endoscopic data, with no gold standard in place. In addition 
to contributing to the initial diagnosis of Crohn’s disease, 
proper small bowel evaluation allows accurate determination 
of both the location and the extent of small bowel disease.20 
The average time between onset of symptoms and Crohn’s 
diagnosis can be more than couple of years, whilst earlier 
treatment of the disease can lead to better clinical outcome 
and improved life quality. It was only natural for WCE to 
find one more ‘solid’ indication.
In another recent meta-analysis, the results of various 
modalities in the diagnosis of Crohn’s were summa-
rized, and it was shown that WCE is superior to any one 
other test in detecting the intestinal lesions of Crohn’s 
disease.1 WCE allows the detection of intestinal lesions 
in a large subset of patients with known Crohn’s disease, 
but also frequently the detection of intestinal lesions in 
patients with a clinical and/or biological suspicion of 
Crohn’s disease with a diagnostic yield of 43%–71%. 
Admittedly, patients with raised inflammatory indexes 
(C-reactive protein, erythrocite sedimentation rate) or 
high fecal calprotectin present better yield in comparison 
to those referred for WCE on the basis of diarrhea or 
abdominal pain.
In 2006, Golder and colleagues compared the diagnostic 
yield of capsule endoscopy and magnetic resonance 
enteroclysis (MRE) in the detection of small bowel Clinical and Experimental Gastroenterology 2009:2 114
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pathologies. They studied a total of 36 patients out of which 
18 had proven or suspected small bowel Crohn’s disease. They 
found that in patients with Crohn’s disease, WCE detected 
significantly more inflammatory lesions in the first two 
segments of the small bowel compared with MRE (12 patients 
vs one patient; p = 0.016). One patient had scattered inflam-
mation of the mucosa. MRE did not reveal any intestinal 
abnormalities in this patient group.21
Marmo and colleagues compared WCE and enteroclysis 
while Voderholzer and colleagues studied WCE versus CT 
enteroclysis in evaluating the extent of small bowel involve-
ment in Crohn’s disease. Both groups found that WCE is 
superior to enteroclysis/CT enteroclysis in estimating the 
presence and extent of small bowel Crohn’s disease.22,23
A simple Capsule Endoscopy Crohn’s Disease Activity 
Index (CECDAI) has been recently devised, in order to allow 
for grading of the severity of small bowel capsule endoscopy 
findings in such cases.24 The investigators divided the small 
bowel into proximal and distal segments (according to 
transit times), and then rated each segment on the basis of 
three parameters: inflammation (A), extent of disease (B), 
and presence of strictures (C). To determine each segmental 
(proximal and distal) score the three subscores were used 
(A × B + C). The CECDAI index is calculated by adding 
both segmental scores.24
A different approach was proposed by Solem and 
colleagues after a blind, prospective study which aimed to 
assess the sensitivity and specificity of WCE, CTE, ileo-
colonoscopy, and small bowel follow-through (SBFT) in 
the diagnosis of small bowel Crohn’s disease. The patients 
included underwent all four tests over a four-day period. The 
investigators concluded that the sensitivity of WCE for active 
small bowel Crohn’s disease was not significantly different 
from CTE, ileocolonoscopy, or SBFT. However, the utility 
of CTE as a first-line test for Crohn’s disease may be limited 
by low specificity, and by the need for prior small bowel 
radiography (due to the high frequency of asymptomatic 
partial small bowel obstruction).25
CTE and MRE can be used for evaluation of bowel wall 
thickness and enhancement, supporting the diagnosis of 
Crohn’s disease. These techniques have the added benefit of 
not only investigating the intestinal wall, but also detecting 
the presence of extra-intestinal abnormalities such as abscess 
formation. Unfortunately, MRE is costly and availability is 
a problem in many regions. It may be effective to use CTE 
as a first-line diagnostic tool and reserving WCE for patients 
suspicious for Crohn’s despite a negative evaluation with 
ileocolonoscopy and CTE.26 Certainly, the recent World 
Organization of Digestive Endoscopy – European Colitis and 
Crohn’s Organization (OMED–ECCO) consensus guideline 
set the scene for the standard use of capsule endoscopy in the 
investigation algorithm of small bowel Crohn’s disease.27
Polyps/small bowel malignancies
Tumors in the small intestine present with abdominal pain 
or intestinal obstruction, weight loss, abdominal mass, and 
anorexia or jaundice rather than GI bleed, therefore only 
one third of these are investigated for OGIB. Small bowel 
neoplasms are uncommon (accounting for approximately 
1%–3% of GI tumors) and abdominal pain is a late sign of 
small bowel cancer. In a recent study, small bowel tumors 
were found to account for 5%–7% of patients presenting with 
obscure bleeding. It is the most common cause in patients 
under 50 years of age presenting with obscure GI bleeding.28 
Angioectasias, although a common capsule finding in all age 
groups, tend to present more frequent in the elderly. Approxi-
mately 60% of tumors are malignant. The most common 
location for both epithelial and nonepithelial small bowel 
tumors is the jejunum, while carcinoids are more common 
in the ileum.25 GI stromal tumors are the most common 
bleeding tumors.
Coeliac disease
The diagnosis of coeliac disease is made by demonstrat-
ing the characteristic histopathological changes of subtotal 
partial atrophy and increased intraepithelial lymphocytes on 
intestinal biopsy obtained by upper GI endoscopy. Serological 
tests include antiendomysial and antitissue transglutamin-
ase antibodies. However, there is a definite place for WCE 
in the diagnosis of this disease, as it provides eight-fold 
magnification, and allows the acquisition of views similar 
to those obtained during dissecting microscopy.29
It can be used not only as an attractive first diagnostic 
step, but also as a monitoring tool in patients with known 
celiac disease to check for healing of the small bowel. Some 
of the limitations of the ‘gold standard’ ie, the difficulty to 
obtain proper oriented tissue samples, the tendency to present 
as patchy mucosal lesions that can too easily be missed on 
biopsy, and the limited portion of the duodenum examined 
by an upper GI endoscopy, along with the risk of failing to 
diagnose coeliac complications are considered the major 
strengths of WCE.29
On the other hand, lesser degrees of villous atrophy can 
be easily missed by WCE, and also the lesions identified by 
capsule endoscopy (especially in cases of complicated coeliac 
disease) will eventually need a biopsy. Overall, capsule Clinical and Experimental Gastroenterology 2009:2 115
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endoscopy seems to be able to recognize the endoscopic 
markers of coeliac disease described in the literature.30
Esophageal WCE
The esophagus is easily accessed by upper GI endoscopies, 
but some patients are concerned about the invasiveness of 
the test, the effects of sedation, and pharyngeal discomfort. 
On top of that, in the Western world there are recently issues 
regarding endoscopy equipment decontamination in relation 
with variant Creutzfeldt-Jakob disease (vCJD). Various 
studies have proved the validity of esophageal capsule for 
Barrett’s esophagus and esophagitis, while its use for the 
detection of varices is undergoing evaluation after few studies 
showed encouraging results.31
Colon WCE
The use of colon capsule is on the take-off; however, 
there are still numerous factors that need addressing prior 
to a wider application of the technique. First of all, the 
purgative regimen used to maintain the cleanliness of the 
colon throughout the transit of the capsule is cumbersome 
and real time viewer is ideal in order to avoid unsuccessful 
investigations. Colon WCE should act as complementary 
to conventional colonoscopy and could be an appropriate 
solution for those patients who are either unwilling or have 
failed colonoscopy, as well as in cases where conventional 
colonoscopy is contraindicated.32 The main long-term 
primary objective of the colon WCE is the average risk 
population undergoing colorectal cancer screening. A recent 
study of a total of 328 patients (mean age, 58.6 years) showed 
that the sensitivity and specificity of capsule endoscopy 
for detecting polyps that were 6 mm in size or bigger were 
64% and 84%, respectively and for detecting advanced 
adenoma, the sensitivity and specificity were 73% and 79%, 
respectively. Of the 19 cancers detected by colonoscopy, only 
14 were detected by capsule endoscopy (sensitivity, 74%; 
95% confidence interval [CI]: 52 to 88). For all lesions, the 
sensitivity of capsule endoscopy was higher in patients with 
good or excellent colon cleanliness than in those with fair 
or poor colon cleanliness. Mild-to-moderate adverse events 
were reported in 26 patients (7.9%) and were mostly related 
to the colon preparation.33 As colon WCE has still some 
limitations (inability to insufflate air, clean or take biopsies), 
future capsule prototypes seem to be necessary.32
Conclusion
A new era has begun with the use of wireless capsule in the 
investigation of the GI tract. The once inapproachable small 
bowel has become a familiar territory and pathologies and 
variations of normality are now images portfolios and atlases. 
It is only certain that the new technology will find more 
applications in the form of controllable capsule endoscopy 
and why not, therapeutic as well.
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